S Africa suspends J&J Covid vaccine after 6 users elsewhere get blood clots

Health Minister emphasised that there had not been any reports of clots that have formed after vaccinations in South Africa

Johnson & Johnson
Press Trust of India Johannesburg
3 min read Last Updated : Apr 15 2021 | 7:28 AM IST

South Africa has joined the US in suspending its rollout of the Johnson & Johnson COVID-19 vaccine, following reports that six women who received the immunisation doses had developed unusual blood clots with low platelet count.

"After this advisory came to my attention, I held urgent consultations with our scientists, who have advised that we cannot take the decision made by the US Food and Drug Administration (FDA) lightly.Based on their advice, we have determined to voluntarily suspend our rollout until the causal relationship between the development of clots and the Johnson and Johnson vaccine is sufficiently interrogated," Health Minister Zweli Mkhize said in a statement on Tuesday evening.

Mkhize emphasised that there had not been any reports of clots that have formed after vaccinations in South Africa, despite 289,787 health care workers already having received the vaccine. All the cases of blood colt-related complications have arisen from the US.

The South African Health Products Regulatory Authority will collate information from Johnson & Johnson, the FDA and other regulatory bodies to make a thorough assessment of the situation and advise us as a regulatory body that has exercised its authoritative powers on the approval of the vaccine in their own right, Mkhize said.

The minister called for patience, saying that the discussion around the suspension might only take a few days.

We hope that the deliberations will only take a few days. Given the preliminary literature on hand, our scientists are confident that the FDA's decision is on a precautionary basis and we expect that this will not result in the complete withdrawal of the Johnson and Johnson vaccine from the vaccination armament, he said.

We are confident that the rollout of Johnson & Johnson will resume and so, with 30 million doses of Johnson & Johnson and 30 million doses of Pfizer secured we now have enough doses to exceed the 40 million we were targeting this year.

This is in line with our commitment to vaccinate as many people as possible in this financial year- in the ideal scenario we would vaccinate every single adult found in South Africa, the minister said.

The minister added that the additional Pfizer vaccines would also not impede the government's vaccine roll-out plan.

This also reassures us that, in the extremely unlikely event that the Johnson and Johnson rollout is completely halted, we will not have any impediment to proceed with phase two of the rollout with Pfizer, he said.

South Africa has so far lost 53,498 lives to COVID-19, along with 1,561,559 confirmed cases, according to Johns Hopkins University.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineCoronavirus TestsSouth Africa

First Published: Apr 15 2021 | 7:12 AM IST

Next Story